Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CRISPR-Cas9 Targeting of PCSK9 in Human Hepatocytes In Vivo-Brief Report.

Arteriosclerosis, thrombosis, and vascular biology - 1 May 2016

Wang Xiao, Raghavan Avanthi, Chen Tao, Qiao Lyon, Zhang Yongxian, Ding Qiurong, Musunuru Kiran

Abstract excerpt

OBJECTIVE: Although early proof-of-concept studies of somatic in vivo genome editing of the mouse ortholog of proprotein convertase subtilisin/kexin type 9 (Pcsk9) in mice have established its therapeutic potential for the prevention of cardiovascular disease, the unique nature of genome-editing technology-permanent alteration of genomic DNA sequences-mandates that it be tested in vivo against human genes in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Clustered Regularly Interspaced Short Palindromic Repeats
Share to CRISPR-Associated Proteins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gene Editing

Share to Gene Targeting

Share to Hepatocytes

Share to Hydrolases

Share to Interleukin Receptor Common gamma Subunit

Share to Proprotein Convertase 9

Source

Open in PubMed Open full text

Identifiers

PMID: 26941020
DOI: 10.1161/ATVBAHA.116.307227
PMCID: PMC4850082

Genes

PCSK9

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CRISPR-Cas9 Targeting of PCSK9 in Human Hepatocytes In Vivo-Brief Report.PMID 26941020Read ↗

Permanent alteration of PCSK9 with in vivo CRISPR-Cas9 genome editing.Semantic proximity Read ↗

In vivo genome and base editing of a human PCSK9 knock-in hypercholesterolemic mouse modelSemantic proximity Read ↗

In Vivo Base Editing of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) as a Therapeutic Alternative to Genome Editing.Semantic proximity Read ↗

Is It Ever Wise to Edit Wild-Type Alleles? Engineered CRISPR Alleles Versus Millions of Years of Human Evolution.Semantic proximity Read ↗

Long-term stable reduction of low-density lipoprotein in nonhuman primates following in vivo genome editing of PCSK9Semantic proximity Read ↗

In vivo liver targeted genome editing as therapeutic approach: progresses and challengesSemantic proximity Read ↗

A CRISPR-Cas9 platform for primary human hepatocytes enables arrayed screening and in vivo validation of HBV host factorsSemantic proximity Read ↗

CRISPR Gene Editing in Lipid Disorders and Atherosclerosis: Mechanisms and OpportunitiesSemantic proximity Read ↗

In vivo CRISPR editing with no detectable genome-wide off-target mutations.Semantic proximity Read ↗

Engineered PsCas9 enables therapeutic genome editing in mouse liver with lipid nanoparticlesSemantic proximity Read ↗

Gene Editing for the Treatment of HypercholesterolemiaSemantic proximity Read ↗

Functional impact of PCSK9 variants on LDL uptake in a knockout hepatic modelSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.